CRSP — Crispr Therapeutics AG Share News
0.000.00%
Last trade - 00:00- $4.98bn
- $3.20bn
- $3.51m
Bluebird signs pact with insurer for sickle cell gene therapy
Street View: Vertex/CRISPR at advantage as FDA approves sickle cell gene therapies
Swiss stocks - Factors to watch on December 11
Biden praises US approval of gene therapies for sickle cell disease
Brief: Vertex And Crispr Therapeutics Announce Us FDA Approval Of Casgevy™ (Exagamglogene Autotemcel) For The Treatment Of Sickle Cell Disease
Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln
US approves two gene therapies for sickle cell disease (updated)
Brief: FDA Approves First Gene Therapies To Treat Patients With Sickle Cell Disease
US approves two gene therapies for sickle cell disease
Crispr Up As Focus On Next: gen therapy candidates
CAR-T therapy developers fall amid U.S. FDA investigation
Jefferies says biotech may see more M&A deals in 2024
U.S. STOCKS ON THE MOVE-Silver miners, Intel, oil stocks
U.S. STOCKS ON THE MOVE-Apollomics, Walmart, Williams-Sonoma
U.S. STOCKS ON THE MOVE-Macy's, Squarespace, Bath & Body Works
U.S. STOCKS ON THE MOVE-Alibaba, Cisco, CRISPR
CRISPR rises after UK authorizes gene therapy for blood disorders
UK authorises gene therapy for blood disorders in world first
CRISPR rises as investors raise hopes on blood disorder therapy